Zhanlu Li1, Yi Luan1, Min Wang1, Ya Li1, Xiaohua Shen1, Guosheng Fu1, Wenbin Zhang2. 1. Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China. 2. Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China. 3313011@zju.edu.cn.
Abstract
BACKGROUND: Obstruction of coronary microcirculation can lead to myocardial ischemia and poor prognosis. Salvianolate exerts cardiovascular protection at cellular levels. However, no studies have confirmed the effect of salvianolate on stable coronary heart disease (CHD) with high fractional flow reserve (FFR) and myocardial microcirculatory disturbances. METHODS/ DESIGN: This study will enroll 78 patients who have stable coronary disease with 50 to 70% stenosis in major coronary arteries and whose FFR > 0.80 and index of microcirculatory resistance (IMR) > 25. Patients will be randomly divided into the salvianolate group or the placebo group. After above evaluations, salvianolate 200 mg will be intravenously dripped immediately for the next 30 min and subsequent 7 days in the salvianolate group, and matching 0.9% normal saline will be arranged in the placebo group. IMR will be reevaluated in immediate phase after first 30 min of salvianolate or placebo treatment. The primary end point will be the IMR change in this phase, and the secondary end points will be the total ischemic burden assessed by the Seattle angina scale, quality of life scale, Holter electrocardiography, and 6-min walk test after 7 days before discharge. DISCUSSION: This study will firstly clarify the improvement effect of salvianolate on coronary microcirculation and provide an effective treatment method for stable CHD patients with high FFR and myocardial microcirculatory disturbance. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1800018772 . Registered on 9 October 2018 and updated on 2 March 2020.
RCT Entities:
BACKGROUND:Obstruction of coronary microcirculation can lead to myocardial ischemia and poor prognosis. Salvianolate exerts cardiovascular protection at cellular levels. However, no studies have confirmed the effect of salvianolate on stable coronary heart disease (CHD) with high fractional flow reserve (FFR) and myocardial microcirculatory disturbances. METHODS/ DESIGN: This study will enroll 78 patients who have stable coronary disease with 50 to 70% stenosis in major coronary arteries and whose FFR > 0.80 and index of microcirculatory resistance (IMR) > 25. Patients will be randomly divided into the salvianolate group or the placebo group. After above evaluations, salvianolate 200 mg will be intravenously dripped immediately for the next 30 min and subsequent 7 days in the salvianolate group, and matching 0.9% normal saline will be arranged in the placebo group. IMR will be reevaluated in immediate phase after first 30 min of salvianolate or placebo treatment. The primary end point will be the IMR change in this phase, and the secondary end points will be the total ischemic burden assessed by the Seattle angina scale, quality of life scale, Holter electrocardiography, and 6-min walk test after 7 days before discharge. DISCUSSION: This study will firstly clarify the improvement effect of salvianolate on coronary microcirculation and provide an effective treatment method for stable CHD patients with high FFR and myocardial microcirculatory disturbance. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1800018772 . Registered on 9 October 2018 and updated on 2 March 2020.
Authors: Marie Mide Michelsen; Naja Dam Mygind; Adam Pena; Ahmed Aziz; Daria Frestad; Nis Høst; Eva Prescott Journal: JACC Cardiovasc Imaging Date: 2016-04
Authors: Daniel F Pauly; B Delia Johnson; R David Anderson; Eileen M Handberg; Karen M Smith; Rhonda M Cooper-DeHoff; George Sopko; Barry M Sharaf; Sheryl F Kelsey; C Noel Bairey Merz; Carl J Pepine Journal: Am Heart J Date: 2011-09-06 Impact factor: 4.749
Authors: Venkatesh L Murthy; Masanao Naya; Viviany R Taqueti; Courtney R Foster; Mariya Gaber; Jon Hainer; Sharmila Dorbala; Ron Blankstein; Ornella Rimoldi; Paolo G Camici; Marcelo F Di Carli Journal: Circulation Date: 2014-04-30 Impact factor: 29.690
Authors: Steven M Bradley; Thomas M Maddox; Maggie A Stanislawski; Colin I O'Donnell; Gary K Grunwald; Thomas T Tsai; P Michael Ho; Eric D Peterson; John S Rumsfeld Journal: J Am Coll Cardiol Date: 2013-10-30 Impact factor: 24.094